Alto Neuroscience (ANRO) Cash from Investing Activities (2023 - 2026)
Alto Neuroscience's (ANRO) quarterly Cash from Investing Activities came in at -$556000.0 in Q1 2026, down 2216.67% year-on-year from $26267.7 in Q1 2025, and down 2216.67% quarter-over-quarter from -$24000.0 in Q1 2025.
Alto Neuroscience (ANRO) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Alto Neuroscience has disclosed Cash from Investing Activities across 4 years of filings, most recently posting -$556000.0 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$556000.0, down 2216.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$556000.0 (up 70.35% YoY), and the FY2025 annual result was -$24000.0, up 98.84% from the prior year.
- Cash from Investing Activities came in at -$556000.0 for Q1 2026 at Alto Neuroscience, down from -$24000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$21000.0 in Q1 2023 to a low of -$1.0 million in Q3 2024.
- The 4-year median for Cash from Investing Activities is -$282000.0 (2024), against an average of -$312500.0.
- Across the five-year window, Cash from Investing Activities plunged 2237.21% in 2024 and surged 89.29% in 2025, its largest moves.
- Alto Neuroscience's Cash from Investing Activities stood at -$352000.0 in 2023, then sank by 43.75% to -$506000.0 in 2024, then soared by 95.26% to -$24000.0 in 2025, then sank by 2216.67% to -$556000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$556000.0 (Q1 2026), -$24000.0 (Q1 2025), and -$506000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Alto Neuroscience | 643.06 Mn | 379.30 Mn | - | -556,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Dec 31, 2024 | -506,000.00 |
| Dec 31, 2024 | -506,000.00 |
| Sep 30, 2024 | -1.01 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -340,000.00 |
| Jun 30, 2024 | -340,000.00 |
| Mar 31, 2024 | -224,000.00 |
| Mar 31, 2024 | -224,000.00 |
| Dec 31, 2023 | -352,000.00 |
| Dec 31, 2023 | -352,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Jun 30, 2023 | -54,000.00 |
| Jun 30, 2023 | -54,000.00 |
| Mar 31, 2023 | -21,000.00 |
| Mar 31, 2023 | -21,000.00 |